Clinical trials: Docetaxel
Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma
Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer
This phase II trial studies how well docetaxel, cisplatin and fluorouracil work in treating patients with previously untreated stage II-IV nasal cavity and/or paranasal sinus cancer.
- Conditions
- Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma, Sinonasal Undifferentiated Carcinoma, Stage II Nasal Cavity and Paranasal Sinus Cancer AJCC v8
- Trial name
- NCT00707473
- Testing
- Carboplatin, Chemoradiotherapy, Cisplatin
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancer
Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer
This phase II trial is studying how well giving sorafenib together with docetaxel and cisplatin works in treating patients with metastatic or locally advanced gastric or gastroesophageal junction cancer that cannot be removed by…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancer, Advanced Unresectable Gastric Cancer
- Trial name
- NCT00253370
- Testing
- BAY 43-9006, docetaxel, cisplatin
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non Small Cell Lung
A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
The primary objective of the study was to demonstrate overall survival improvement for aflibercept + docetaxel compared to docetaxel + placebo as second line treatment for participants with locally advanced or metastatic…
- Trial name
- VITAL (NCT00532155)
- Testing
- Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Docetaxel (Taxotere®), Dexamethasone (pre- and post-medication for docetaxel)
- Where
- 32 sites in United States, Argentina and 30 more
- Volunteers
- 913 people
- Sponsor
- Sanofi
Stomach Cancer
Study of Docetaxel, Capecitabine and Oxaliplatin in Advanced Stomach Cancer
Considering synergism between docetaxel (D), capecitabine (X), and oxaliplatin (O) and favourable toxicity profile of oxaliplatin over cisplatin, it is to be expected that combination of docetaxel, capecitabine, and oxaliplatin…
- Trial name
- NCT00446290
- Testing
- Docetaxel, Capecitabine and Oxaliplatin
- Where
- South Korea
- Volunteers
- 22 people
- Sponsor
- Asan Medical Center
Prostate Cancer
Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer
This randomized study is looking at the benefits of using docetaxel (chemotherapy) added to one of the standard treatments (radiation and hormones) for men with high-risk prostate cancer.
- Trial name
- NCT00116142
- Testing
- Docetaxel, Androgen Hormonal Suppression and Radiation, Androgen Suppression Therapy and Radiation Therapy
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- Dana-Farber Cancer Institute
Esophageal Cancer
Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00551759
- Testing
- 5-Fluorouracil, Oxaliplatin, Cetuximab
- Where
- 109 sites in United States
- Volunteers
- 22 people
- Sponsor
- Eastern Cooperative Oncology Group
Neoplasms
Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling
This phase IB trial aims to identify anticancer activity of GSK3052230 in subjects with malignancies with abnormal dependence on FGF pathway signaling.
- Trial name
- NCT01868022
- Testing
- GSK3052230, paclitaxel, carboplatin
- Where
- 29 sites in United States, Belgium and 5 more
- Volunteers
- 65 people
- Sponsor
- GlaxoSmithKline
High-grade Serous Ovarian Carcinoma, Ovarian Carcinoma
Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)
The primary objective is to evaluate in participants with high-grade serous ovarian cancer (HGSOC), whether the reduction from baseline in circulating tumor deoxyribonucleic acid (ctDNA) at Cycle 3 (ΔctDNA) is larger in…
- Trial name
- NCT05446870
- Testing
- Pembrolizumab, Paclitaxel, Carboplatin
- Where
- 45 sites in United States, Belgium and 9 more
- Volunteers
- 160 people
- Sponsor
- Merck Sharp & Dohme LLC
Head and Neck Squamous Cell Carcinoma
Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
This phase II trial studies the side effects and how well docetaxel and capecitabine work in treating patients with squamous cell (thin, flat cells) carcinoma of the head and neck that has come back or spread to other places in…
- Trial name
- NCT02524275
- Testing
- Capecitabine, Docetaxel, Quality-of-Life Assessment
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- University of Nebraska
Non-small Cell Lung Cancer
Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)
To assess the 2 year survival of patients with Stage III unresectable non-small cell lung cancer receiving consolidation gemcitabine or gemcitabine plus docetaxel following concurrent chemotherapy and radiation.
- Trial name
- NCT00191139
- Testing
- gemcitabine, docetaxel, cisplatin
- Where
- 15 sites in United States, Argentina and 2 more
- Volunteers
- 64 people
- Sponsor
- Eli Lilly and Company
Esophageal Cancer
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
This is an open-label, Phase 1/2 study to evaluate the safety of durvalumab (MEDI4736) in combination with oxaliplatin/capecitabine chemotherapy in metastatic/locally advanced oesophageal cancer (OC) and with neoadjuvant…
- Trial name
- NCT02735239
- Testing
- Durvalumab, Tremelimumab, Oxaliplatin
- Where
- 4 sites in United Kingdom
- Volunteers
- 73 people
- Sponsor
- Ludwig Institute for Cancer Research
Adenocarcinoma of the Pancreas, Stage IA Pancreatic Cancer
Perioperative Therapy for Resectable Pancreatic Cancer
This phase II trial studies how well giving combination chemotherapy together with intensity-modulated radiation therapy (IMRT) and surgery works in treating patients with localized pancreatic cancer that can be removed by…
- Conditions
- Adenocarcinoma of the Pancreas, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer
- Trial name
- NCT00609336
- Testing
- gemcitabine hydrochloride, docetaxel, capecitabine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Washington
Castration-Resistant Prostate Cancer
Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy
This is a phase 3 study to compare the clinical benefit of MDV3100 versus placebo in patients with castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy.
- Trial name
- AFFIRM (NCT00974311)
- Testing
- Enzalutamide
- Where
- 249 sites in United States, Argentina and 13 more
- Volunteers
- 1,199 people
- Sponsor
- Pfizer
Ovarian Cancer, Peritoneal Cavity Cancer
Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00227721
- Testing
- Docetaxel, Gemcitabine hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Robert Morris
Non-small Cell Lung Cancer
Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer
The purpose of this study is to evaluate the benefit of adding suramin at a non-cytotoxic dose to carboplatin and docetaxel regimen in the treatment of chemo-naïve patients with non-small cell lung cancer.
- Trial name
- NCT01038752
- Testing
- Suramin Drug:Docetaxel Drug: Carboplatin
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Optimum Therapeutics, LLC
Metastatic Prostate Cancer
A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer
Background: Prednisone and docetaxel have been used successfully in treating patients with prostate cancer, either when used alone or in combination with other agents.
- Trial name
- NCT00942578
- Testing
- Bevacizumab, Lenalidomide, Docetaxel
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer
Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC
This is an open-label, single institution, phase II study of Sorafenib in combination with docetaxel and carboplatin in patients with advanced non-small cell lung cancer.
- Trial name
- NCT00647426
- Testing
- Sorafenib + Docetaxel/Carboplatin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Neoplasms
Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor
To determine the best dose of this investigational agent AG-013736 in combination with various standard of care treatments for advanced solid tumors.
- Trial name
- NCT00454649
- Testing
- Axitinib + Paclitaxel + Carboplatin (Cohort 1), Axitinib + Paclitaxel + Carboplatin (Cohort 2), Axitinib + Paclitaxel + Carboplatin (Cohort 3)
- Where
- 13 sites in United States, Poland and 1 more
- Volunteers
- 102 people
- Sponsor
- Pfizer
Lung Cancer
Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00970684
- Testing
- bevacizumab, docetaxel, gemcitabine hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Nathan Pennell, MD, PhD
Ewing's Sarcoma
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
A two-part trial in patients with metastic Ewing's sarcoma. Participants in Part 1 will be randomized to receive either Vigil immunotherapy or gemcitabine and docetaxel with the objective of comparing the overall survival between…
- Trial name
- NCT02511132
- Testing
- Vigil, Temozolomide, Irinotecan
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Gradalis, Inc.